RxDoctor Payments Data

David Sinclair, MD

Clinical Neurophysiology · Jackson, MSNPI 1235391046

Payments from drug & device makers

$4,623in general payments, 2019–2025

Across 192 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$721
  • Eisai Inc.$480
  • Lundbeck LLC$379
  • AbbVie$354
  • Acadia Pharmaceuticals Inc$334
  • Amylyx Pharmaceuticals, Inc.$283
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$241%
  • Food & beverage$4,59999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,195
Medicare patients
421
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate13$130,258
Kesimpta PenOfatumumab11$93,644
Emgality PenGalcanezumab-Gnlm74$65,292
RytaryCarbidopa/Levodopa18$29,999
BelsomraSuvorexant51$26,761
QuliptaAtogepant11$15,534
Aimovig AutoinjectorErenumab-Aooe15$15,257
Propranolol Hcl ErPropranolol Hcl201$7,007
Rivastigmine18$5,494
MovantikNaloxegol Oxalate14$5,443
Gabapentin280$4,684
Memantine Hcl138$3,691
RizatriptanRizatriptan Benzoate108$2,340
Quetiapine Fumarate71$2,283
Diclofenac Sodium56$2,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$124$130,25813 claims
Amneal Pharmaceuticals LLCRytary$29$29,99918 claims
AbbVieQulipta$354$15,53411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Jackson

Where these figures come from

Is this you, or does something look wrong? →